Melinda Sheffield-Moore, Ph.D.
Professor, Division of Endocrinology
Melinda Sheffield-Moore, Ph.D.
Faculty, Cell Biology Graduate Program
Director, Translational Technologies Key Resource, Institute of Translational Sciences (ITS)
Assistant Program Director, ITS-Clinical Research Center (CRC)
Director, Core and Imaging Laboratories, ITS-CRC
Division of Endocrinology
Department of Internal Medicine
University of Texas Medical Branch
301 University Blvd
J5.100 John Sealy Towers, Route 0264
Galveston, Texas 77555-0264
Dr. Sheffield-Moore's research program is focused on the metabolic and molecular mechanisms behind the cachexia of cancer and the sarcopenia of aging. In the past 14 years at UTMB, she has directed as PI or Co-I human clinical translational research projects in healthy and diseased populations employing a variety of clinical and molecular medicine based techniques to examine skeletal muscle protein metabolism and skeletal muscle microvascular blood flow. These projects have sought to identify the mechanisms and pathways responsible for skeletal muscle atrophy during cancer, aging, inactivity, bedrest/hospitalization, and trauma and burns. Additionally, her research has also employed various clinical interventions to identify the mechanisms and pathways responsible for skeletal muscle hypertrophy including vasodilators, testosterone, amino acids and exercise.
Her laboratory has been at the leading edge of novel in vivo techniques such as contrast-enhanced ultrasound, used to non-invasively measure skeletal muscle tissue perfusion in an effort to dissect the role of muscle perfusion in age-related muscle loss. Finally, she is studying the efficacy of nutrition and testosterone at preventing or reducing cancer-related muscle loss in patients with cervical or head and neck cancer.
- Fellow, Sealy Center on Aging (SCOA)
- Fellow, Claude Pepper Aging Center
- UTMB Cancer Center, Division of Rehabilitation Sciences
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Order set
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medications
- Parenteral Opioids
- Sepsis, Adult ICU
- 111 - Stroke Alert
- 112 - Stroke Activation
- 300086 - Stroke Floor Admission
- 3000000001 - Stroke Critical care without tPA
- 300088 Stroke - Transfer from Critical care to floor
- 3004002 - Stroke Discharge
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.